amezalpat (TPST-1120) / Tempest Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
amezalpat (TPST-1120) / Tempest Therap
Morpheus-Liver, NCT04524871 / 2020-001743-10: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers

Recruiting
1/2
518
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab 15 mg/kg, Avastin, Tiragolumab, Tocilizumab, Actemra, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
Hoffmann-La Roche, Adagene Inc, Tempest Therapeutics, NiKang Therapeutics, Inc., Immune-Onc Therapeutics
Advanced Liver Cancers
08/26
08/26
NCT03829436: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Completed
1
38
US
Part 1 TPST-1120, Experimental, Part 2 TPST-1120 + nivolumab, Experimental + Opdivo, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab
Tempest Therapeutics
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
09/22
09/22

Download Options